Other Routine +

Perimeter Selected for INOVAIT Pilot Fund to Advance AI for Breast Cancer Surgery

FDA-approved AI surgical imaging pioneer secures minor R&D grant as commercial ramp remains early-stage and cash-burn persists

By The Northwire Desk — AI Analysis Jun 09, 2026 · 09:05 PINK · 0.3 Perimeter Medical Imaging AI, Inc.

Executive Summary

Perimeter Medical Imaging AI has been selected for the INOVAIT Pilot Fund to advance next-generation AI capabilities for its FDA-approved Claire™ intraoperative imaging platform.
The project will receive up to nearly $148,000 in government contributions and a $100,000 Mitacs internship award.
The initiative is conducted in partnership with the University of Toronto and focuses on reducing manual labeling burdens, optimizing AI performance across tissue types, and deploying a two-tier AI architecture for operating room hardware.
Future deployment of these AI enhancements will proceed in accordance with standard FDA review processes for Class III devices.
The clinical objective is to address the ~25% rate of follow-on surgeries in breast-conserving procedures by providing surgeons with real-time, AI-driven microscopic tissue visualization and margin assessment.

Material Impact

Financial impact: Negligible. The total grant and award value (~$248,000) is immaterial relative to the company's recent $13.5M+ in financing and multi-million dollar operating budget. It does not alter the capitalization or near-term liquidity position.
Strategic impact: Incremental. The grant validates ongoing R&D efforts post-FDA PMA approval and aligns with the company's stated focus on AI infrastructure. It is a standard academic partnership model for medical device developers.
Market impact: Low. The market already priced in the FDA approval and commercial launch trajectory. This is a routine R&D update that does not introduce new revenue streams or change the commercialization timeline.

PINK · Price

Company Overview

Perimeter Medical Imaging AI develops optical coherence tomography (OCT) imaging systems for intraoperative tissue visualization.
Flagship product: Claire OCT+AI, which received FDA Premarket Approval (PMA) in March 2026, making it the first AI-enabled imaging device approved in the U.S. for intraoperative breast cancer margin assessment.
Legacy product: S-Series OCT, FDA 510(k) cleared for general tissue imaging, generating recurring revenue through leases and consumables.
Target market: ~300,000 annual U.S. breast-conserving surgeries, with plans to expand into other oncology indications and biopsy procedures.
Strategic partnerships include system-wide agreements with Intermountain Health and HCA HealthONE Rose, providing a foothold in the U.S. healthcare system.

More from Perimeter Medical Imaging AI, Inc.